High Lipoprotein(a) Predicts Cardiac Events in DM With PCI

Share this content:
High Lipoprotein(a) Predicts Cardiac Events in DM With PCI
High Lipoprotein(a) Predicts Cardiac Events in DM With PCI

WEDNESDAY, Dec. 7, 2016 (HealthDay News) -- For patients with diabetes mellitus (DM) undergoing percutaneous coronary intervention (PCI), high lipoprotein(a) (Lp[a]) levels are associated with advanced cardiac events, according to a study published in the Dec. 15 issue of The American Journal of Cardiology.

Hirokazu Konishi, M.D., Ph.D., from Juntendo University Shizuoka Hospital in Japan, and colleagues examined the role of Lp(a) in patients with DM who underwent PCI. Data were included for 1,136 eligible patients, who were divided into two groups based on the median of Lp(a) levels (high Lp[a], 575 patients and low Lp[a], 561 patients). Patients were followed for a median of 4.7 years.

The researchers found that the event rate of all-cause death was not significantly different between the groups. The high Lp(a) group had significantly higher cumulative incidence of cardiac death and acute coronary syndrome than the low Lp(a) group. High Lp(a) was an independent predictor of cardiac death and acute coronary syndrome in multivariable analysis (hazard ratio, 1.2).

"In conclusion, a high Lp(a) value could be associated with advanced cardiac events after PCI for patients with DM," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »